Recent studies have questioned treatment of serious methicillinresistant Staphylococcus aureus (MRSA) infections with vancomycin because of treatment failures, despite vancomycin MICs in the susceptible category (MIC Յ 2 g/ml) (2, 3, 5, 6, 7). Some of these studies have used broth microdilution for determining vancomycin MICs (5), while others have used the Etest commercial product (AB Biodisk, Solna, Sweden) (2, 7). We sought to determine if substantive differences might result from using different susceptibility test methods for determining vancomycin MICs.
those generated by the CLSI reference broth microdilution and agar dilution methods reflect a one dilution-higher vancomycin MIC when determined by the Etest. It is widely held that the precision of a dilution susceptibility test method is plus or minus one twofold dilution. Thus, it is unprecedented that a single dilution difference in the vancomycin MIC in the range of 0.5 to 2 g/ml would have significant clinical implications. Until further evidence is generated to determine if such small differences in the vancomycin MIC are indeed significant, therapeutic recommendations should specify the MIC method on which the recommendations are based. 
